药物对比
Eptinezumab vs Atogepant
Eptinezumab（Vyepti）与 Atogepant（Qulipta）用于偏头痛：两者均靶向CGRP。Eptinezumab 为静脉注射，Atogepant 为口服。疗效相似；可选择注射剂或片剂。
此页面暂无可用的对比维度。
临床背景
Patients comparing CGRP monoclonal antibodies and receptor antagonists for chronic or episodic migraine prevention.
结论
Both Eptinezumab and Atogepant are effective options for migraine prevention by targeting CGRP, with the choice depending on whether an injectable or oral medication is preferred.
全部药物对比